194 related articles for article (PubMed ID: 12090757)
1. Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells.
Spence MJ; Streiff R; Day D; Ma Y
Cytokine; 2002 Apr; 18(1):26-34. PubMed ID: 12090757
[TBL] [Abstract][Full Text] [Related]
2. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
Park JI; Strock CJ; Ball DW; Nelkin BD
Mol Cell Biol; 2003 Jan; 23(2):543-54. PubMed ID: 12509453
[TBL] [Abstract][Full Text] [Related]
3. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
4. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor.
Wang Y; Robledo O; Kinzie E; Blanchard F; Richards C; Miyajima A; Baumann H
J Biol Chem; 2000 Aug; 275(33):25273-85. PubMed ID: 10854424
[TBL] [Abstract][Full Text] [Related]
5. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
[TBL] [Abstract][Full Text] [Related]
6. Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells.
Halfter H; Friedrich M; Postert C; Ringelstein EB; Stögbauer F
Mol Cell Biol Res Commun; 1999 May; 1(2):109-16. PubMed ID: 10356359
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue.
Rega G; Kaun C; Weiss TW; Demyanets S; Zorn G; Kastl SP; Steiner S; Seidinger D; Kopp CW; Frey M; Roehle R; Maurer G; Huber K; Wojta J
Circulation; 2005 Apr; 111(15):1938-45. PubMed ID: 15837947
[TBL] [Abstract][Full Text] [Related]
8. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
10. Signaling of type II oncostatin M receptor.
Auguste P; Guillet C; Fourcin M; Olivier C; Veziers J; Pouplard-Barthelaix A; Gascan H
J Biol Chem; 1997 Jun; 272(25):15760-4. PubMed ID: 9188471
[TBL] [Abstract][Full Text] [Related]
11. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?
Sriram K; Benkovic SA; Hebert MA; Miller DB; O'Callaghan JP
J Biol Chem; 2004 May; 279(19):19936-47. PubMed ID: 14996842
[TBL] [Abstract][Full Text] [Related]
12. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways.
Demyanets S; Kaun C; Rychli K; Rega G; Pfaffenberger S; Afonyushkin T; Bochkov VN; Maurer G; Huber K; Wojta J
Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1962-8. PubMed ID: 17604327
[TBL] [Abstract][Full Text] [Related]
13. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of oncostatin M and leukaemia inhibitory factor expression in astrocytoma cells.
Kasza A; Rogowski K; Kilarski W; Sobota R; Bernas T; Dobrucki J; Travis J; Koj A; Bugno M; Kordula T
Biochem J; 2001 Apr; 355(Pt 2):307-14. PubMed ID: 11284716
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway.
Li WQ; Dehnade F; Zafarullah M
J Immunol; 2001 Mar; 166(5):3491-8. PubMed ID: 11207308
[TBL] [Abstract][Full Text] [Related]
16. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway.
Stancato LF; Sakatsume M; David M; Dent P; Dong F; Petricoin EF; Krolewski JJ; Silvennoinen O; Saharinen P; Pierce J; Marshall CJ; Sturgill T; Finbloom DS; Larner AC
Mol Cell Biol; 1997 Jul; 17(7):3833-40. PubMed ID: 9199317
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes.
Kasza A; Kiss DL; Gopalan S; Xu W; Rydel RE; Koj A; Kordula T
J Neurochem; 2002 Nov; 83(3):696-703. PubMed ID: 12390531
[TBL] [Abstract][Full Text] [Related]
18. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Podewski EK; Hilfiker-Kleiner D; Hilfiker A; Morawietz H; Lichtenberg A; Wollert KC; Drexler H
Circulation; 2003 Feb; 107(6):798-802. PubMed ID: 12591746
[TBL] [Abstract][Full Text] [Related]
19. gp130-Dependent signalling pathway is not enhanced in gp130 transgenic heart after LIF stimulation.
Tone E; Kunisada K; Kumanogoh A; Negoro S; Funamoto M; Osugi T; Kishimoto T; Yamauchi-Takihara K
Cytokine; 2000 Oct; 12(10):1512-8. PubMed ID: 11023666
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells.
Klausen P; Pedersen L; Jurlander J; Baumann H
Oncogene; 2000 Jul; 19(32):3675-83. PubMed ID: 10951574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
